These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8526382)

  • 1. Prospective study on the diagnosis and prognosis of lung cancer by using new simultaneously observed seromarkers.
    Zhang Q; Ren H; Wang B
    Ann N Y Acad Sci; 1995 Sep; 768():337-40. PubMed ID: 8526382
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum tumour markers in lung cancer.
    Hansen M
    Scand J Clin Lab Invest Suppl; 1991; 206():93-101. PubMed ID: 1658919
    [No Abstract]   [Full Text] [Related]  

  • 3. Elastase levels in small and non-small cell lung carcinoma.
    Güner G; Kirkali G; Baskin Y; Karlikaya C; Akkoçlu A
    Biochem Soc Trans; 1993 Aug; 21 ( Pt 3)(3):305S. PubMed ID: 8224451
    [No Abstract]   [Full Text] [Related]  

  • 4. [T1-2N0M0-stage lung cancer, its diagnosis and treatment results].
    Perel'man MI; Denisov LE; Odintsov SV
    Ter Arkh; 1989; 61(7):128-31. PubMed ID: 2555930
    [No Abstract]   [Full Text] [Related]  

  • 5. Soluble interleukin 2 receptor (sIL2R) in monitoring advanced lung cancer during chemotherapy.
    Brunetti G; Bossi A; Baiardi P; Jedrychowska I; Pozzi U; Bacchella L; Bernardo G
    Lung Cancer; 1999 Jan; 23(1):1-9. PubMed ID: 10100141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue polypeptide antigen in bronchogenic carcinoma.
    Zatloukal P; Glagolicová A; Linhart M; Sebes A; Hencl P; Mĕricka O
    Neoplasma; 1993; 40(5):301-3. PubMed ID: 8272159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer.
    Milman N; Pedersen LM
    Oncol Rep; 2002; 9(1):193-8. PubMed ID: 11748482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum pleiotrophin could be an early indicator for diagnosis and prognosis of non-small cell lung cancer.
    Du ZY; Shi MH; Ji CH; Yu Y
    Asian Pac J Cancer Prev; 2015; 16(4):1421-5. PubMed ID: 25743809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
    Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
    Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pulmonary carcinoma. The effect of assessing histologic type on the prognosis].
    Santangelo A; Turra G; Fantini A; Morgutti L
    Minerva Med; 1989 Jul; 80(7):689-91. PubMed ID: 2550850
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer.
    Maeda Y; Segawa Y; Takigawa N; Takata I; Fujimoto N
    Intern Med; 1996 Oct; 35(10):764-71. PubMed ID: 8933183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The staging of lung cancer.
    Little AG; DeMeester TR; MacMahon H
    Semin Oncol; 1983 Mar; 10(1):56-70. PubMed ID: 6301065
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of CYFRA 21-1 in malignant and benign pleural effusions.
    Toumbis M; Rasidakis A; Passalidou E; Kalomenidis J; Alchanatis M; Orphanidou D; Jordanoglou J
    Anticancer Res; 1996; 16(4A):2101-4. PubMed ID: 8712750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of neuron-specific enolase, carbohydrate antigen 19-9 and carbohydrate antigen 125 in carcinoma of the lung.
    Oktay G; Güner G; Karlikaya C; Akkoçlu A
    Biochem Soc Trans; 1995 May; 23(2):211S. PubMed ID: 7672232
    [No Abstract]   [Full Text] [Related]  

  • 16. Elevated plasma thymosin-alpha1 levels in lung cancer patients.
    Sasaki H; Fujii Y; Masaoka A; Yamakawa Y; Fukai I; Kiriyama M; Saito Y; Matsui H
    Eur J Cardiothorac Surg; 1997 Dec; 12(6):885-91. PubMed ID: 9489875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer.
    Matsuyama W; Hashiguchi T; Mizoguchi A; Iwami F; Kawabata M; Arimura K; Osame M
    Chest; 2000 Oct; 118(4):948-51. PubMed ID: 11035661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients.
    Köhler J; Schuler M; Gauler TC; Nöpel-Dünnebacke S; Ahrens M; Hoffmann AC; Kasper S; Nensa F; Gomez B; Hahnemann M; Breitenbuecher F; Cheufou D; Özkan F; Darwiche K; Hoiczyk M; Reis H; Welter S; Eberhardt WE; Eisenacher M; Teschler H; Stamatis G; Schmiegel W; Hahn SA; Baraniskin A
    J Cancer Res Clin Oncol; 2016 Apr; 142(4):795-805. PubMed ID: 26687686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers and IL-2R in lung cancer.
    Marino P; Preatoni A; Fonticoli L; Parodi M; Tarolo GL
    Recenti Prog Med; 1990 Nov; 81(11):702-4. PubMed ID: 1962891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
    Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.